Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rademikibart (CBP-201) in adults with moderate to severe atopic dermatitis
NCT04444752Phase 2Completed
- Sponsor
- Connect Biopharma
- Start
- Jul 2020
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of rademikibart in atopic dermatitis (AD), sponsored by Connect Biopharma. Started Jul 2020; status: completed.
02
Drugs
rademikibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04444752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04444752.